20/20 Biolabs Inc (NASDAQ:AIDX – Get Free Report) was the target of a significant drop in short interest during the month of October. As of October 15th, there was short interest totaling 11,270 shares, a drop of 75.0% from the September 30th total of 45,167 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily volume of 131,753 shares, the short-interest ratio is currently 0.1 days.
20/20 Biolabs Stock Performance
AIDX stock traded up $0.02 during midday trading on Wednesday, reaching $0.25. 141,224 shares of the company traded hands, compared to its average volume of 402,959. The firm has a market capitalization of $3.32 million and a price-to-earnings ratio of -0.46. 20/20 Biolabs has a 52-week low of $0.23 and a 52-week high of $50.00. The business has a 50 day moving average of $0.44 and a 200-day moving average of $1.00.
20/20 Biolabs (NASDAQ:AIDX – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.26) earnings per share (EPS) for the quarter. The company had revenue of $0.73 million during the quarter.
Analyst Ratings Changes
Separately, Weiss Ratings raised 20/20 Biolabs from a “sell (e-)” rating to a “sell (e)” rating in a report on Monday, August 3rd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $5.00.
View Our Latest Research Report on 20/20 Biolabs
20/20 Biolabs Company Profile
We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.
See Also
- Five stocks we like better than 20/20 Biolabs
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.
